Last reviewed · How we verify
NCT01964703
Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study
Phase 4 trial testing Rubus occidentalis extract in Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance) in 29 participants. Completed.
1 October 2013
Quick facts
| Lead sponsor | Korea University Anam Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 1 April 2013 |
| Primary completion | 1 October 2013 |
Drugs / interventions tested
- Rubus occidentalis extract — full drug profile →
Conditions studied
- Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance) — all drugs for Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance) →
Sponsor
Korea University Anam Hospital
Who can join
19 and older, any sex, with Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
serum glucose (fasting and post 75g oral glucose tolerance test)
Time frame: 12 weeks
Sponsor's own description
The purpose of this study is to determine whether Rubus occidentalis extract could improve fasting or postprandial serum glucose levels, and related metabolic markers among patients with prediabetes (impaired fasting glucose and/or impaired glucose tolerance).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Rubus Occidentalis Extract on Metabolic Parameters in Subjects with Prediabetes: A Proof-of-concept, Randomized, Double-blind, Placebo-controlled Clinical Trial.
An JH, Kim DL, Lee TB, Kim KJ, et al · · 2016 · cited 27× · PMID 27279471 · DOI 10.1002/ptr.5664
Verify or expand the search:
- PubMed search for NCT01964703
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Korea University Anam Hospital trials
Trials by the same sponsor.
- NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
- NCT07280780 — CGM-Based Glycemic Analysis After ESI · not yet recruiting
- NCT07189000 — Patient-centered REhabilitation Program to Advance REcovery · NA · not yet recruiting
- NCT07246148 — NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization · NA · recruiting
- NCT07376980 — The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01964703 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea University Anam Hospital
- Last refreshed: 14 October 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01964703.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing